Manufacturing and Operations - The company is expanding manufacturing capacity and establishing fill/finish capabilities, which will require substantial additional expenditures and regulatory approvals [270]. - Manufacturing facilities in Rensselaer, New York, and Limerick, Ireland, are critical for producing bulk products for commercial supply and clinical candidates [273]. - The company recorded inventory write-down charges related to REGEN-COV for both 2022 and 2021, indicating potential issues with excess inventory [273]. - Manufacturing processes for biologics are complex, and minor deviations can lead to product defects or recalls, impacting inventory levels [275]. - The company relies on single-source suppliers for certain raw materials, which poses risks if these suppliers fail to deliver [276]. - Regulatory compliance with cGMPs is essential, and any non-compliance could lead to delays in product approvals and increased costs [278]. - The FDA issued a Complete Response Letter (CRL) for the company's BLA for linvoseltamab due to inspection findings, delaying potential approval [278]. - The company may need to develop or acquire additional manufacturing capabilities for new drug technologies, which entails significant risks and costs [270]. Legal and Regulatory Risks - The company faces risks related to product liability claims, which could arise even if harm is unrelated to its products [279]. - The company is subject to healthcare fraud and abuse laws, which could result in civil or criminal penalties if violated [282]. - The company is subject to the federal civil False Claims Act, which prohibits knowingly presenting false claims for payment to the federal government, with potential civil monetary penalties and criminal fines for violations [283]. - The company participates in various government pricing programs, including the Medicaid Drug Rebate program, which requires compliance with complex pricing and rebate calculations that can significantly impact financial results [289]. - In September 2024, CMS modified regulations governing the Medicaid Drug Rebate Program, potentially increasing costs and complexity of compliance for the company [292]. - The company has obligations to report average sales prices for certain drugs to the Medicare program, with potential negative impacts on operations from changes in statutory or regulatory guidance [294]. - The company faces risks related to improper conduct by employees or agents, which could lead to civil or criminal investigations and negatively impact its reputation and financial condition [297]. - The company is involved in civil proceedings initiated by the U.S. Department of Justice concerning certain business activities, which could harm its business and financial condition [285]. - Changes in laws and regulations affecting the healthcare industry could have a materially negative impact on the company's business operations and financial results [300]. Financial and Tax Risks - The company may incur additional tax liabilities due to operations in various jurisdictions, influenced by factors such as changes in tax laws and regulations, which could materially affect the effective tax rate and cash flows [306]. - The OECD Pillar Two framework has influenced tax laws in countries where the company operates, including the implementation of minimum taxes, potentially impacting the effective tax rate and cash flows [307]. - The company may need to raise additional funds for future acquisitions, which could result in shareholder dilution or increased indebtedness [319]. - As of December 31, 2024, the company had an aggregate of $2.704 billion in outstanding indebtedness under senior unsecured notes and lease financing facilities [331]. - The company reported $2.488 billion in cash and cash equivalents and $15.424 billion in marketable securities, including $1.095 billion in equity securities as of December 31, 2024 [332]. - The investment portfolio would decrease in fair value by approximately $163.0 million with a 100 basis point unfavorable change in interest rates as of December 31, 2024 [450]. - The company does not currently use interest rate derivative instruments to manage exposure to interest rate changes [451]. International Operations and Compliance - The company has large-scale manufacturing operations in Limerick, Ireland, and has established offices in multiple countries, making it vulnerable to changes in regulatory regimes that could adversely affect business operations [305]. - The company is expanding its operations internationally, which exposes it to risks associated with compliance with foreign laws, including the Foreign Corrupt Practices Act [298]. - The company is required to report any "transfers of value" made to U.S. licensed physicians and teaching hospitals, with potential penalties for non-compliance [286]. - The company’s operations are affected by geopolitical factors, such as the Russia-Ukraine conflict, which may impact the ability to attract and retain qualified personnel and affect business operations [306][318]. - The company has exposure to foreign exchange risk as international sales grow, and strategies including foreign currency hedging will be implemented [456]. Data Privacy and Security Risks - The company faces risks related to the personal data collected, processed, and shared, which are regulated by evolving privacy and data protection laws, including GDPR, that impose significant compliance costs [308][310]. - The company is subject to various federal and state laws governing data privacy, including HIPAA and FTC regulations, which could result in penalties if not complied with [309]. - The company’s use of social media and AI-based platforms poses risks related to data security and privacy laws, which could lead to reputational damage and liability [313]. - The company faces risks from significant disruptions of information technology systems and potential data security breaches, which could impact operations and financial condition [324][325]. Business Operations and Market Risks - The company relies on third-party collaborators, such as Sanofi and Bayer, for the development and commercialization of products, and any failure by these collaborators could adversely affect business operations and financial condition [314][316]. - The company’s commercial capabilities outside the United States are limited and would need to be developed or outsourced, particularly for products co-commercialized with collaborators [315][317]. - The company may face challenges in maintaining sales of marketed products like EYLEA and Dupixent in the face of competition and regulatory developments [334]. - The company has experienced significant volatility in its stock price, influenced by various market factors and the concentration of ownership among a small number of shareholders [334][336]. - Public health outbreaks, such as the COVID-19 pandemic, have previously adversely affected the company's operations and may continue to do so in the future [329][330]. Shareholder and Governance - The board of directors authorized a share repurchase program of up to $3.0 billion, with $1.917 billion remaining available as of December 31, 2024 [337]. - In February 2025, a quarterly cash dividend program was initiated, with the first quarter 2025 cash dividend declared [337]. - As of December 31, 2024, holders of Class A Stock held 14.4% of the combined voting power of all shares, allowing them to significantly influence corporate decisions [338]. - Current executive officers and directors beneficially owned 5.4% of outstanding shares of Common Stock and 17.2% of combined voting power [339]. - Two customers accounted for 79% of net trade accounts receivables as of December 31, 2024, indicating significant credit risk concentration [453].

It has been less than a month since I initiated coverage on Regeneron (NASDAQ: REGN ), suggesting that the company represented a BUY based on promising growth from LIBTAYO and DUPIXENT and stabilizing sales in theBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (REGN 4.53%) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and full-year 2024 results before market open, and investors were clearly impressed by the numbers. Regeneron's price zoomed well higher than the S&P 500 index's trajectory, which was a rise of 0.7% on the day.A crushing bottom-line beatThe quarter saw Regeneron grow its revenue by 10% year over year to just under $3 ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ --  Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Regeneron and certai ...

Regeneron Pharmaceuticals, Inc. (REGN) reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the year-ago period.The upside in the bottom line can be attributed to higher revenues.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi (SNY) for Dupixent, higher Eylea HD and L ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

On Tuesday, Regeneron Pharmaceuticals Inc REGN reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29.The company reported sales of $3.79 billion, up 10%, beating the consensus of $3.75 billion.“Regeneron’s financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurchase capacity,” said Leo ...

Regeneron (REGN) reported $3.79 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.3%. EPS of $12.07 for the same period compares to $11.86 a year ago.The reported revenue represents a surprise of +0.07% over the Zacks Consensus Estimate of $3.79 billion. With the consensus EPS estimate being $11.62, the EPS surprise was +3.87%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.87%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $11.75 per share when it actually produced earnings of $12.46, delivering a surprise of 6.04%.Over the last four quarter ...

Exhibit 99.1 Press Release Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43 Annual J.P. Morgan Healthcare Conference Dupixent is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD and EYLEA remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudi ...